Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study

Open access

Abstract

BACKGROUND: Potentially modifiable risk factors including obesity, diabetes, hypertension, and smoking are associated with Alzheimer disease (AD) and represent promising targets for intervention. However, the causality of these associations is unclear. We sought to assess the causal nature of these associations using Mendelian randomization (MR). METHODS AND FINDINGS: We used SNPs associated with each risk factor as instrumental variables in MR analyses. We considered type 2 diabetes (T2D, NSNPs = 49), fasting glucose (NSNPs = 36), insulin resistance (NSNPs = 10), body mass index (BMI, NSNPs = 32), total cholesterol (NSNPs = 73), HDL-cholesterol (NSNPs = 71), LDL-cholesterol (NSNPs = 57), triglycerides (NSNPs = 39), systolic blood pressure (SBP, NSNPs = 24), smoking initiation (NSNPs = 1), smoking quantity (NSNPs = 3), university completion (NSNPs = 2), and years of education (NSNPs = 1). We calculated MR estimates of associations between each exposure and AD risk using an inverse-variance weighted approach, with summary statistics of SNP-AD associations from the International Genomics of Alzheimer's Project, comprising a total of 17,008 individuals with AD and 37,154 cognitively normal elderly controls. We found that genetically predicted higher SBP was associated with lower AD risk (odds ratio [OR] per standard deviation [15.4 mm Hg] of SBP [95% CI]: 0.75 [0.62-0.91]; p = 3.4 × 10(-3)). Genetically predicted higher SBP was also associated with a higher probability of taking antihypertensive medication (p = 6.7 × 10(-8)). Genetically predicted smoking quantity was associated with lower AD risk (OR per ten cigarettes per day [95% CI]: 0.67 [0.51-0.89]; p = 6.5 × 10(-3)), although we were unable to stratify by smoking history; genetically predicted smoking initiation was not associated with AD risk (OR = 0.70 [0.37, 1.33]; p = 0.28). We saw no evidence of causal associations between glycemic traits, T2D, BMI, or educational attainment and risk of AD (all p > 0.1). Potential limitations of this study include the small proportion of intermediate trait variance explained by genetic variants and other implicit limitations of MR analyses. CONCLUSIONS: Inherited lifetime exposure to higher SBP is associated with lower AD risk. These findings suggest that higher blood pressure--or some environmental exposure associated with higher blood pressure, such as use of antihypertensive medications--may reduce AD risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001841

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Mendelian randomization estimates of the association of systolic blood pressure with AD in individual ADGC studies and overall in ADGC, GERAD1, and IGAP. This figure shows MR estimates for the association of SBP-associated variants with AD in each of the participant studies in ADGC [24] and in GERAD1 [25] using individual SNP-level data compared to that observed in IGAP [12] using summary-level data. See S1 Text (supplemental results) for individual study name abbreviations.
Fig 1 Mendelian randomization estimates of the association of systolic blood pressure with AD in individual ADGC studies and overall in ADGC, GERAD1, and IGAP. This figure shows MR estimates for the association of SBP-associated variants with AD in each of the participant studies in ADGC [24] and in GERAD1 [25] using individual SNP-level data compared to that observed in IGAP [12] using summary-level data. See S1 Text (supplemental results) for individual study name abbreviations.CC BY · PubMed Central
Fig 2 Associations of the systolic blood pressure genetic score with quantitative traits in the EPIC-InterAct study. This figure shows the investigation of pleiotropic associations of genetic score for SBP with quantitative traits in the EPIC-InterAct study [26]. Effect sizes are expressed in SDs per SBP-raising allele. Analyses were adjusted for age, sex, center of recruitment, and subcohort status.
Fig 2 Associations of the systolic blood pressure genetic score with quantitative traits in the EPIC-InterAct study. This figure shows the investigation of pleiotropic associations of genetic score for SBP with quantitative traits in the EPIC-InterAct study [26]. Effect sizes are expressed in SDs per SBP-raising allele. Analyses were adjusted for age, sex, center of recruitment, and subcohort status.CC BY · PubMed Central
Fig 3 Association of the systolic blood pressure genetic score with systolic blood pressure by age stratum in the EPIC-InterAct subcohort. This figure shows the association between the genetic score for SBP and SBP in the EPIC-InterAct study by age stratum [26]. Analyses were adjusted for sex, center of recruitment, and subcohort status.
Fig 3 Association of the systolic blood pressure genetic score with systolic blood pressure by age stratum in the EPIC-InterAct subcohort. This figure shows the association between the genetic score for SBP and SBP in the EPIC-InterAct study by age stratum [26]. Analyses were adjusted for sex, center of recruitment, and subcohort status.CC BY · PubMed Central
Fig 4 Associations of the systolic blood pressure genetic score with binary outcomes in the EPIC-InterAct study. This figure shows the investigation of pleiotropic associations of the genetic score for SBP with binary outcomes in the EPIC-InterAct study [26]. The OR per SBP-raising allele is shown.
Fig 4 Associations of the systolic blood pressure genetic score with binary outcomes in the EPIC-InterAct study. This figure shows the investigation of pleiotropic associations of the genetic score for SBP with binary outcomes in the EPIC-InterAct study [26]. The OR per SBP-raising allele is shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 203

Metadata

Authors
Østergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., Gibbons, L. E., Alzheimer’s Disease Genetics Consortium, The GERAD1 Consortium, EPIC-InterAct Consortium, Larson, E. B., Powell, J. F., Langenberg, C., Crane, P. K., Wareham, N. J., & Scott, R. A.
Affiliations
  • Aarhus University (DK)
  • University of Washington (US)
  • University of Cambridge (GB)
  • King's College London (GB)
  • Brigham Young University (US)
  • University of California, San Francisco (US)
  • Kaiser Permanente Washington Health Research Institute (US)
Corresponding author
Scott, Robert A.
Venue
PLOS Medicine
Published
2015-06-16
Volume
12
Issue
6
Pages
e1001841
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W605291159
Cited by
203
References
51
Citations by year
2026: 8 · 2025: 14 · 2024: 15 · 2023: 17 · 2022: 16 · 2021: 36 · 2020: 23 · 2019: 23 · 2018: 17 · 2017: 17 · 2016: 13 · 2015: 4
FWCI
13.81
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Research Portal (Queen's University Belfast) (submittedVersion, cc-by)
  • DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • Site cant be reached (submittedVersion, cc-by)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
  • Bristol Research (University of Bristol) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Funders
  • Howard Hughes Medical Institute
  • U.S. Department of Veterans Affairs (U01 AG024904)
  • Juvenile Diabetes Research Foundation International
  • Alzheimer's Association (IIRG-05–14147, K01 AG030514, U01 AG016976, U01 AG032984, IIRG-08-89720, U01 AG024904, U24AG021886)
  • Dana Foundation (K01 AG030514, U01 AG024904)
  • Bristol-Myers Squibb (U01 AG024904, AG024904)
  • Eli Lilly and Company (U01 AG024904, AG024904)
  • Pfizer (AG024904, 115372, U01 AG024904)
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis (FP7/2007-2013)
  • Office of Research and Development
  • F. Hoffmann-La Roche (AG024904, U01 AG024904)
  • Medpace (U01 AG024904)
  • Synarc (U01 AG024904, K01 AG030514)
  • South London and Maudsley NHS Foundation Trust
  • Wellcome Trust (FP7/2007–2013, 089703, 081864, 115372)
  • European Federation of Pharmaceutical Industries and Associations (FP7/20072013, 115372)
  • Alzheimer's Society
  • Alzheimer's Research Trust
  • National Institute for Health and Care Research (115372, NF-SI-0512-10033, FP7/2007–2013, K01 AG030514, U01 AG024904, NF-SI-0512-10135, CL-2011-18-004)
  • University of Cambridge
  • King's College London
  • Newcastle University
  • European Commission (U01 AG024904, LSHM_CT_2006_037197, 2007–2013, FP7 2007-2013, FP7/2007, 115372)
  • Cardiff University
  • Bundesministerium für Bildung und Forschung
  • Stichting MS Research
  • Elan (U01 AG024904)
  • Lundbeckfonden (R165–2013–15320)
  • Eisai (U01 AG024904, AG024904)
  • North Bristol NHS Trust
  • Alfried Krupp von Bohlen und Halbach-Stiftung
  • Universitat de Barcelona
  • Hersenstichting
  • University College London Hospitals NHS Foundation Trust
  • H. Lundbeck A/S (U01 AG024904, AG024904)
  • Heinz Nixdorf Stiftung
  • National Institutes of Health (5rc2ag036502-02, UL1TR001108, FP7/2007-2013, 5r01ag027944-05, 5u01ag024904-10, 7r01ag019757-06, 5r37ag015473-15, AG016976, U01-AG024904, AG024904, AG019610, AG021886, MH60451, U01 AG10483, AG10483, AG013846, UL1TR001445)
  • Genentech (AG024904, U01 AG024904)
  • Canadian Institutes of Health Research
  • Medical Research Council (MR/L023784/2, FP7/20072013, MR/K006584/1, U01 AG024904, MC_PC_13048, MC_UU_12015/2, MR/L501529/1, MR/L010305/1, K01 AG030514, MC_UU_12015/1, MC_G1000734, MR/L023784/1)
  • Economic and Social Research Council (ES/L008238/1)
  • Menzies Centre for Australian Studies, King's College London, University of London
  • Helmholtz Zentrum München
  • National Institute on Aging (U01-AG-024904, R01AG017917, AG 10483, P01AG010491, P50 AG016575, AG 016976, AG05 128, P30AG010129, P30AG010133, R01AG019085, P30 AG 08051, P50AG005144, R01AG042611, U01‐AG10483, R01AG33193, P50 AG016576, R01AG030146, AG021547, R01 AG30146, AG036535, AG010491, R01‐AG17917, AG-05144, U24 AG026390, P30AG028383, R01 AG15819, P30AG012300, R01AG041718, AG 025688, P50AG016577, U01-AG-06781, P50AG005133, R01-AG027944, AG 024904, AG 030,514, P30AG028377, U01AG006781, U01AG016976, P50AG005131, R01-AG019757, R37-AG015473, P50AG005138, R01AG026390, AG041718, R01AG022374, P50AG016570, AG019610, K01AG030514, R01AG011101, AG036528, P50AG005128, P30AG010124, P50AG016573, AG019757, R01AG021547, R01AG041232, R01AG030653, U01AG010483, R01AG015819, P30AG008017, P30AG010161, U01AG032984, R01AG012101, CA129769, R01AG031581, P30AG008051, RC2-AG036502, P50AG016582, P50AG008702, AG032984, AG013846, AG-06781, P50AG005681, P50AG005142, P50AG008671, P30AG019610, R01AG026916, P50AG005146, P01 AG0 3991, P01AG003991, 1RC2AG036502, U24AG026395, P30AG013846, P50AG005136, P50AG005134, RC2AG036535, P30AG013854, R01AG025259, P50AG025688, AG026395, R01AG017173, RC2AG036528, R01AG033193, P01AG002219, AG021886, R01AG013616, P30 AG-10133, P01AG019724, U24AG021886, P30AG062421, P50AG023501, AG027944, R01AG020688, AG 030653, P50AG016574, R01AG035137, AG041232)
  • National Institute of Mental Health (U01 AG024904, MH60451, R01MH080295, P50MH060451)
  • National Human Genome Research Institute (U01HG008657, U01HG004610, U01HG006375)
  • National Cancer Institute (R01CA129769, U54CA132378)
  • National Institute of Allergy and Infectious Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Neurological Disorders and Stroke (NS3 9764, R01NS059873, MH60451, NIMH MH60451, P50NS039764, FP7/2007-2013)
  • National Institute of Environmental Health Sciences (P30ES013508)
  • National Institute of Biomedical Imaging and Bioengineering (U01 AG024904, AG024904)
  • National Institute of Child Health and Human Development
  • National Center for Research Resources (MO1 RR000-96, UL1RR02777, UL1RR029893, M01RR000096)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, modifiable risk factors, systolic blood pressure, smoking, type 2 diabetes, fasting blood glucose, insulin resistance, body mass index, serum lipids, cholesterol, triglycerides, antihypertensive drugs, educational attainment, causal inference, genetic variants, intervention targets, cognitive aging, dementia prevention, cardiovascular risk factors, glycemic traits
MeSH terms
Alzheimer Disease, Female, Humans, Male, Risk Factors, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. https://app.cochat.ai/papers/10.1371/journal.pmed.1001841
The paper
Østergaard, S. D., Mukherjee, S., Sharp, S. J., Proitsi, P., Lotta, L. A., Day, F., Perry, J. R. B., Boehme, K. L., Walter, S., Kauwe, J. S., Gibbons, L. E., Alzheimer’s Disease Genetics Consortium, The GERAD1 Consortium, EPIC-InterAct Consortium, Larson, E. B., Powell, J. F., Langenberg, C., Crane, P. K., Wareham, N. J., & Scott, R. A. (2015). Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1001841

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.